regulatory T (Treg) cells, which can be generated either in the thymus or in the peripheral in respond to chronic challenges, are known to play key roles in maintaining immunological homeostasis and the control of autoimmune deviation or diseases. In a recent issue of Nature Immunology, two independent studies from Harvard Medical School described the transcriptional signature of effector Th17 and Treg cells and unveiled very different mechanisms in instructing these two cell types.
1,2
Th17 cells are characterized by their capacities to produce IL-17A, IL-17F, IL-21 and IL-22. In vivo, these cells are present at the site of tissue inflammation in many autoimmune diseases and are thought to be the critical drivers of autoimmune tissue inflammation and damage. In vitro, IL-17 expressing cells can be differentiated by a combination of the cytokines transforming growth factor (TGF)-b1 and IL-6. However, Th17 cells induced by TGF-b1 and IL-6 in vitro do not readily induce autoimmune inflammation and need additional exposure to another cytokine IL-23 to become pathogenic. 3 The analysis of IL-23R 2/2 mice also revealed the essential role of the IL-23 signal in Th17 cell-mediated pathogenesis, since decreased Th17 function and reduced susceptibility to experimental autoimmune encephalomyelitis (EAE) were observed in those mice. 4 However, how IL-23 drives pathogenic Th17 cells is yet to be clarified. In this issue of Nature Immunology, Lee et al., from Vijay K Kuchroo's laboratory, identified TGF-b3 as a key downstream factor of IL-23 responsible for the driving of pathogenic Th17 cells.
By using detailed microarray analysis of the gene expression in Th17 cells induced under different conditions, the authors first found that TGF-b3 was substantially induced in Th17 cells and this induction depended on the presence of the IL-23 signal, suggesting the role of TGF-b3 in IL-23 induced pathogenic differentiation of Th17 cells. This hypothesis was later proven by the experiments showing that Th17 cells could also be induced by using IL-6 plus TGF-b3 instead of TGF-b1. More importantly, TGF-b3-induced Th17 cells were as potent as Th17 cells induced by TGF-b1, IL6 and IL-23 for inducing EAE. Finally, the authors performed additional microarray analysis on Th17 cells induced by either TGF-b1 1 IL-6 1 IL-23 or TGFb3 1 IL-6 and defined the transcriptional signature of pathogenic Th17 cells, represented by 233 genes differentially expressed in pathogenic Th17 cells compared to non-pathogenic Th17 cells. Among which, 23 of them are closely relevant to the pathogenic functions of Th17 cells, including the elevated expression of distinct chemokines and cytokines (Cxcl3, Ccl4, Ccl5, Ccl3, Csf2, Il3, Il22 and Casp1), transcription factors Tbx21 and STAT4 and several effector molecules, such as Gzmb, Lag2 and Lglas. Pathogenic Th17 cells also downregulate the expression of IL-10, IL9, IL1Rn and Ikzf3, which are upregulated in non-pathogenic Th17 cells. Upregulation of Tbx1 (which encodes transcription factor T-bet) in pathogenic Th17 cells is also well consistent with the essential role of T-bet in the pathogenesis of Th17 cells. Interestingly, the defect of pathogenic Th17 cells in Tbx1 2/2 mice could be overcome by the treatment of TGF-b3, suggesting that T-bet might regulate the endogenous expression of TGF-b3. In summary, this study revealed the essential function of IL-23/TGFb-3 axis in driving pathogenic Th17 cells, as judged by their capacity to induce both the 'pathogenic signature' and the actual pathogenic functions of these cells.
In the same issue of Nature Immunology, Fu et al., from Diane Mathis and Christophe Benoist's laboratory, used a large scale transcriptome profiling analysis approach to study the signature of CD4 of the transcription factors that interact with FoxP3. By using the context likelihood of relatedness algorithm, the authors were able to align the key transcription factors according to their contribution 'scores' to the expression of this Treg signature. As expected, this analysis identified FoxP3 as the top predicted regulator with the highest score. It also revealed a number of other transcriptional regulators of the Treg signature, including Eos, Helios, Lef1 and GATA-1, some were shown previously to be associated with Treg cell function. 5, 6 The actual contributions of four transcription factors, Eos, GATA-1, Xbp1 and Helios, were then verified by direct expression profiling of Treg cells from the knockout mice of these genes. Surprisingly, the Treg signatures in each of these mutated mice were not altered significantly compared to wild-type cells. This finding was intriguing but consistent with the normal Treg cell numbers and functions in these mice as shown previously. [7] [8] [9] However, this observation did not exclude the contributions of these factors to the stabilization of Treg cells. Indeed, when the authors overexpressed these factors together with FoxP3, they found that overexpression of FoxP3 alone only led to a small fraction of Treg signature genes, while the co-expression of any of these factors with FoxP3 was capable of inducing the full Treg signature robustly. Two inputs were thus needed to work synergistically to 'lock in' the Treg signature and the establishment of the stable Treg cell state. The 'two key' control system diminishes the risk of the erroneous activation of Treg cells under the circumstances when FoxP3 is transiently induced. More interestingly, as judged by the expression pattern of the 'Treg signature', five of the factors (including Eos, IRF4, GATA-1, Lef1 and Satb1) regulated the same set of genes together with FoxP3, which revealed the multiple redundancy of this lock-in process. It is worth mentioning that, although this study showed that the synergistic effect can be mediated by five different factors, the list might still be incomplete. This redundancy not only ensures additional stability, but also allows several different physiological pathways to arrive at the same state, which may be relevant to the different thymic and extra-thymic context of Treg cell differentiation. Different conditions might each induce one or another cofactor to enable a 'lock-in' of the Treg cell transcriptional network.
Taken together, these two papers described the essential factors in driving or maintaining either pathogenic Th17 cells or Treg cells using the transcriptional signature as a marker. Both pathogenic Th17 cells and Treg cells are tightly controlled, since both Th17 and Treg cells require at least two different factors to reach a fully functional state (either to be pathogenic for Th17 cells or to be 'locked in' for stable Treg cells). Although a definitive surface marker is still not available, pathogenic Th17 cells and 'locked-in' Treg cells can now be defined by their transcription signature as described in both papers. Extensive analysis of these 'expression signatures' and associated experimental evidence in these two reports also leads to our understanding of the process or architecture of the differentiation of these cells, which are very different. Pathogenic Th17 cells are driven strictly by the IL-23/TGF-b3 axis. In contrast, Treg cells have multiple choices of many different factors or pathways (including, but not limited to, the five factors identified by Fu et al.) to fulfill their differentiation (Figure 1 ). These different regulation modes well represent the nature of the immune system. The immune system is doing its best to maintain homeostasis and prevent autoimmunity, which could be achieved by inducing Treg cells through many different ways under different circumstances or at different locations. For each deliberate immune response against infection, when an effective clearing of pathogens is necessary, the immune system also manages to keep the reaction well controlled to prevent excessive activation and self-destruction, which makes it crucial to keep the pathogenesis pathways well constrained in multiple steps. 
